Drug intelligence / Profile preview

SER-314

Development stage: Preclinical
Lead developer: Serentrix
Modality: Small Molecules

Overview

SER-314 is a small molecule antagonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor, currently in pre-clinical development by Serentrix for the treatment of acute pancreatitis. TRPV1 is a non-selective cation channel that plays a critical role in the transmission of pain and the mediation of neurogenic inflammation. SER-314 is part of a series of compounds designed to inhibit TRPV1 activity while specifically avoiding the hyperthermia (elevated body temperature) side effects that hindered earlier generations of TRPV1 antagonists. By blocking TRPV1, SER-314 aims to reduce the inflammatory response and associated pain in patients suffering from acute pancreatitis.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on SER-314.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SER-314.

Explore the full profile